RECRUITING

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Official Title

Use of Natural Language Processing ChatBot and Automated Continuous Activity Monitoring Via Mobile Phones for Early Detection and Management of Symptoms in Patients Undergoing Cancer Treatment

Quick Facts

Study Start:2023-05-22
Study Completion:2025-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05318027

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults (age \>18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
  2. * Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
  3. * Ability read and respond in English
  4. * Ability to provide informed consent to participate in the study
  1. * Patients who are bed bound at baseline (ECOG 4)
  2. * Patients who rely on a wheelchair for ambulation

Contacts and Locations

Study Contact

Michell Kim
CONTACT
215-760-2487
Michell.Kim@pennmedicine.upenn.edu

Principal Investigator

Arun Goel, MD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Kristine Kim, MD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Nishant Shah, MD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania

Study Locations (Sites)

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Arun Goel, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania
  • Kristine Kim, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania
  • Nishant Shah, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-22
Study Completion Date2025-05

Study Record Updates

Study Start Date2023-05-22
Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

  • Lung Cancer
  • Gastrointestinal Cancer
  • Head and Neck Cancer